Mallinckrodt

Mallinckrodt
MedTech

Mallinckrodt sells immunotherapy business for $925M

Special pharmaceutical company Mallinckrodt is selling its photopheresis business, Therakos, to CVC Capital Partners for $925 million.
Heather Landi Aug 5, 2024 3:25pm
arrow back backwards u-turn turn around reverse

Silence takes back 2 complement programs from Mallinckrodt

Mar 28, 2023 10:42am
FDA

FDA approves Mallinckrodt's regenerative skin burn graft

Jun 15, 2021 5:18pm
FDA Building 2

FDA rejects Mallinckrodt's kidney drug over risk-benefit doubts

Sep 14, 2020 8:25am
FDA Building

Mallinckrodt's kidney failure med squeaks by FDA panel 8-7

Jul 15, 2020 6:27pm
FDA

FDA staff question endpoint for Mallinckrodt's terlipressin

Jul 14, 2020 12:28pm